查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609456

非侵入性产前检查 (NIPT) 市场评估:产品·手法·用途·终端用户·各地区的机会及预测 (2018-2032年)

Non-Invasive Prenatal Testing Market Assessment, By Product, By Method,, By Application, By End-user, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 232 Pages | 商品交期: 3-5个工作天内

价格

全球非侵入性产前检测 (NIPT) 市场规模预计将从 2024 年的 69.1 亿美元增长到 2032 年的 207 亿美元，预测期内复合年增长率为 14.70%。

非侵入性产前检测 (NIPT) 市场的主要驱动力是对更安全筛检选择的需求不断增加、孕产妇年龄的增加以及对遗传疾病的认识不断提高。 NIPT 技术的进步、支持性报销政策和策略合作伙伴关係也进一步推动了市场成长。

NIPT 是一种利用母体血液样本进行非侵入性筛检胎儿染色体异常的筛检测试。它主要分析母亲血液中胎儿的游离DNA，特别用于检测三体性疾病，如唐氏症（21三体）、爱德华兹症候群（18三体症）、帕陶症候群（13三体）等。 NIPT 通常在怀孕 10 週时进行，已被证明准确率超过 99%。

对 NIPT 的需求不断增长正在推动新产品的推出，而公司加强诊断产品组合的努力也进一步推动了市场成长。

本报告提供全球非侵入性产前检查 (NIPT) 的市场调查，彙整市场定义和概要，市场规模的转变·预测，各种区分·地区/各主要国家的详细分析，产业结构，影响市场成长因素的分析，案例研究，竞争情形，主要企业简介等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 全球非侵入性产前检查 (NIPT) 市场展望

  • 市场规模的分析·预测
  • 市场占有率的分析·预测
    • 各产品
    • 各手法
    • 各用途
    • 各终端用户
    • 各地区
    • 企业占有率分析
  • 市场地图分析

第5章 北美的非侵入性产前检查 (NIPT) 市场展望

  • 市场规模的分析·预测
  • 市场占有率的分析·预测
  • 各国市场评估
    • 美国
    • 加拿大
    • 墨西哥

第6章 欧洲的非侵入性产前检查 (NIPT) 市场展望

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 土耳其
  • 波兰

第7章 亚太地区的非侵入性产前检查 (NIPT) 市场展望

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第8章 南美的非侵入性产前检查 (NIPT) 市场展望

  • 巴西
  • 阿根廷

第9章 中东·非洲的非侵入性产前检查 (NIPT) 市场展望

  • 沙乌地阿拉伯
  • UAE
  • 南非

第10章 供需分析

第11章 价值链分析

第12章 波特的五力分析

第13章 大环境分析

第14章 价格分析

第15章 市场动态

  • 推动市场要素
  • 市场课题

第16章 市场趋势·展开

第17章 相关法规·革新

第18章 专利形势

第19章 案例研究

第20章 竞争情形

  • 前五名公司的竞争矩阵
  • 前五名公司的SWOT分析
  • 前十大企业的形势
    • Illumina, Inc.
    • Eurofins LifeCodexx GmbH
    • Myriad Genetics, Inc.
    • Natera, Inc.
    • CENTOGENE N.V.
    • PerkinElmer Inc.
    • F. Hoffmann-La Roche Ltd
    • MedGenome Labs Limited
    • Laboratory Corporation of America Holdings
    • BGI Genomics Co., Ltd.

第21章 策略性建议

第22章 关于本公司·免责声明

Product Code: MX12383

Global non-invasive prenatal testing (NIPT) market is projected to witness a CAGR of 14.70% during the forecast period 2025-2032, growing from USD 6.91 billion in 2024 to USD 20.70 billion in 2032. Increased demand for safer screening options, increased maternal age, and an increased awareness of genetic disorders are the key drivers of the non-invasive prenatal testing (NIPT) market. Advances in NIPT technology, supportive reimbursement policies, and strategic partnerships will further help to fuel the market's growth.

NIPT is a screening test for fetal chromosomal abnormalities that is conducted using a non-invasive maternal blood sample. It analyzes mainly fetal cell-free DNA from the maternal bloodstream, detecting especially trisomy disorders such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13), as well as many other sex chromosome disorders. NIPT is usually performed during 10 weeks of gestation and is proven to have an accuracy level greater than 99%.

Ongoing expansion of non-invasive prenatal testing services across regions underscores the significant growth of the market. In October 2024, Yourgene Health Ltd, part of the Novacyt group, and Genetix S.A. launched its first non-invasive prenatal testing service in Colombia. This is the first expansion of Yourgene Health Ltd in Latin America, an area historically underserved in advanced prenatal diagnostics.

The rising requirement for non-invasive testing is bolstering the launch of new products. The efforts by the companies to strengthen their diagnostics portfolio are further fueling the market's growth. For instance, in March 2024, BillionToOne, Inc., a molecular diagnostics company, launched BabyPeek. This non-invasive test detects non-medical traits of a baby, like eye color and food preferences, from maternal blood. Moreover, in April 2024, Strand Life Sciences Pvt. Ltd, a Reliance Industries Ltd. subsidiary, expanded its prenatal diagnostics portfolio through the launch of CNSeq and MaatriSeq tests in India. These streamlined, precision tests, developed to meet Indian-specific requirements, support India's rare disease program and are most likely to fuel the market's expansion in the coming years.

Increasing Prevalence of Chromosomal Abnormalities Boosts Market Demand

The high prevalence of chromosomal abnormalities, often the main cause of miscarriage, is driving the demand for NIPT. A study published in November 2023 in Nature Medicine (Springer Nature Limited) found that 50.4% of spontaneous miscarriages are attributed to problems with chromosomes and the rising maternal and paternal ages. Conditions such as Down's syndrome, Edwards syndrome, and Patau's syndrome have become increasingly prevalent among elderly mothers, resulting in growing demand for early safety testing procedures. NIPT offers a non-invasive blood test alternative to traditional testing, reassuring parents and reducing risks associated with traditional testing.

Furthermore, the growth of the NIPT market is fueled by rising awareness, as couples tend to engage in proactive screening. For instance, in September 2024, KK Women's and Children's Hospital (KKH) partnered with Temasek Foundation to launch a genetic screening program - Temasek Foundation PREDICT (PaREnthood genetic DIsease Carrier Test) Programme in Singapore. The program is designed to screen over 80 severe recessive genetic disorders and provides free genetic counseling and testing services. This program is also expected to raise awareness among couples, address their genetic health needs, and help prospective parents in informed decision-making regarding family planning, thus supporting the market's growth.

Advancements in NIPT Drive Market Growth

Advancements in NIPT, such as increased sensitivity and specificity, allow for better detection of genetic abnormalities, which in turn drives the growth of the market. Improvements in gene sequencing techniques and advanced bioinformatics analysis of cell-free DNA can expand the range of detectable conditions. The increased sensitivity and specificity make it a preferred choice for expectant parents as it can give more accurate results. Therefore, such advancements create more demand for enhanced NIPT.

Additionally, various medical testing companies are also working on introducing advanced testing solutions to enhance patient convenience and combat the various challenges currently being faced by the healthcare sector. In May 2024, Natera, Inc. launched a cfDNA-based test determining fetal RhD status as early as nine weeks to address the current-day shortages of RhIg therapy. Unlike most NIPT labs, Natera's test evaluates fetal RhD and accurately identifies complex variants. This innovation, validated with more than 650 confirmed outcomes, reached 100% sensitivity and over 99% specificity, further supporting safer patient care. Such introductions are expected to enhance the confidence of healthcare professionals and patient populations in novel NIPT's and provide lucrative growth opportunities to the market.

Novel Product Launches Support Market Expansion

The growth in the non-invasive prenatal testing (NIPT) market is primarily driven by the frequent launches of new tests. This trend highlights that more and more people are embracing NIPTs due to their relatively safe and accurate nature. Manufacturers now focus on developing highly advanced NIPTs and strategic partnerships to enhance their market presence. Innovations in testing are expected to ensure better accuracy, wider testing abilities, and easier accessibility, promoting the market's growth. Frequent release of NIPTs keeps the market highly and actively responsive to change as the healthcare conditions evolve, further enabling healthy growth in the NIPT industry. For instance, in April 2023, Mediclinic Southern Africa (Pty) Ltd. introduced a safe and non-invasive prenatal test for expectant parents as part of their DNA-based testing services. The new NIPT builds on the huge success of their previous testing launch and will detect common chromosomal conditions that exist in the fetus. It uses a simple maternal blood test that can identify potential genetic risks as early as nine weeks. Thus, it ensures early disease detection and increases patient confidence in novel diagnostic solutions, supporting the expansion of the market.

Consumables Dominate the Non-Invasive Prenatal Testing (NIPT) Market

The consumables segment holds the largest share in the non-invasive prenatal testing (NIPT) market mainly because of the enormous demand for consumables, reagents, and assay kits for the successful completion of the testing procedures. These products find extensive applications in the clinical setting. Additionally, the rising adoption of NIPTs by expectant parents due to increasing awareness about the importance of genetic screening and growing awareness about chromosomal anomalies is further propelling the requirement for consumables.

Meanwhile, instruments account for the second leading share of the market. Novel product launches in various regions across the globe support the growth of this segment. For instance, in November 2023, Yourgene Health Ltd (Yourgene Health), a subsidiary of Novacyt UK Holdings Ltd, deployed the first NIPT workflow in Morocco at Centre de Biologie Rabat Hay Riad, which is based on the IONA test. Brand-named the COSY test by Laboriad, this high-tech screening device identifies risks in terms of trisomy 21, 18, and 13 within three days.

North America Accounts for Major Share in the Non-Invasive Prenatal Testing (NIPT) Market

North America leads the global NIPT market due to the increasing adoption of non-invasive prenatal testing and the high prevalence of chromosomal abnormalities among neonates in the region. Key North American companies commercially provide advanced NIPT solutions, increasing the accessibility of NIPTs across the United States and Canada. Growing awareness among pregnant couples and healthcare professionals has increased demand; expanded insurance coverage in the U.S. has also made NIPT more accessible, thereby reducing out-of-pocket payments. Furthermore, other enabling policies and well-developed reimbursement structures further facilitate adoption, cementing North America's leadership in the global NIPT market and ensuring the widespread availability of these crucial prenatal screening solutions. The increasing launch of novel technologies and services in the region also supports the market's expansion. For instance, in May 2024, Igentify Ltd., in New York, launched a new NIPT and pharmacogenomics service on its Digital Genetic Assistant platform, strengthening support for patients and clinicians.

Future Market Scenario (2025-2032F)

The NIPT market is expected to grow further due to ongoing technological advancements and an increasing need for precise prenatal testing. Growing awareness about genetic disorders and their expanded benefits should help reinforce the significance of NIPT in prenatal health management.

Furthermore, technological advancements in non-invasive prenatal testing, especially those coming through sequence technologies such as next-generation sequencing, are expected to provide lucrative growth opportunities to the market in the future. For example, Illumina NIPT uses whole-genome sequencing through cell-free DNA to detect chromosomal abnormalities with high sensitivity and specificity. The availability of novel technologies with increased accuracy is further expected to fuel the market's expansion.

Moreover, in September 2023, Gene Solutions, JSC, a fast-growing Vietnamese biotech firm, received USD 21 million in funds to expand its presence in Southeast Asia. Such investments are also expected to provide significant opportunities for the market's growth as they allow companies to expand their geographical presence and focus on developing novel technologies and products.

Key Players Landscape and Outlook

The key players in the NIPT market are enhancing their positions through investments in the procurement of significant product portfolios and concentrated efforts toward research and development activities. Strategic alliances, new product launches, and acquisitions allow them to expand their market presence and result in sustained leadership.

In January 2024, BGI Genomics Co. Ltd. launched the ultra-fast, non-invasive prenatal testing product NIFTY, which is designed to utilize small as well as medium throughput of the DNBSEQ-G99 platform. The platform helps get quick and accurate results for timely genetic counseling and prenatal diagnostics. The innovation further bolsters the company's position in the market.

In January 2024, Natera, Inc. acquired the reproductive health assets of Invitae Corporation, including its non-invasive prenatal and carrier screening business. The upfront payment was made of USD 10 million, while the milestone payments could amount to USD 42.5 million. Natera views the acquisition of Invitae's reproductive health assets as a strategy that expands its non-invasive prenatal screening portfolio and turns the company into market leadership.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Product
      • 4.2.1.1. Instruments
      • 4.2.1.2. Consumables
        • 4.2.1.2.1. Kits
        • 4.2.1.2.2. Reagents
    • 4.2.2. By Method
      • 4.2.2.1. Next Generation Sequencing (NGS)
      • 4.2.2.2. Polymerase Chain Reaction (PCR)
      • 4.2.2.3. Cell-free DNA (cfDNA)
      • 4.2.2.4. Others
    • 4.2.3. By Application
      • 4.2.3.1. Down Syndrome (Trisomy 21)
      • 4.2.3.2. Edwards Syndrome (Trisomy 18)
      • 4.2.3.3. Patau Syndrome (Trisomy 13)
      • 4.2.3.4. Turner Syndrome (Monosomy X)
      • 4.2.3.5. Others
    • 4.2.4. By End-user
      • 4.2.4.1. Hospitals
      • 4.2.4.2. Diagnostic Laboratories
      • 4.2.4.3. Clinics
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia-Pacific
      • 4.2.5.4. South America
      • 4.2.5.5. Middle East and Africa
    • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 4.3. Market Map Analysis, 2024
    • 4.3.1. By Product
    • 4.3.2. By Method
    • 4.3.3. By Application
    • 4.3.4. By End-user
    • 4.3.5. By Region

5. North America Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product
      • 5.2.1.1. Instruments
      • 5.2.1.2. Consumables
        • 5.2.1.2.1. Kits
        • 5.2.1.2.2. Reagents
    • 5.2.2. By Method
      • 5.2.2.1. Next Generation Sequencing (NGS)
      • 5.2.2.2. Polymerase Chain Reaction (PCR)
      • 5.2.2.3. Cell-free DNA (cfDNA)
      • 5.2.2.4. Others
    • 5.2.3. By Application
      • 5.2.3.1. Down Syndrome (Trisomy 21)
      • 5.2.3.2. Edwards Syndrome (Trisomy 18)
      • 5.2.3.3. Patau Syndrome (Trisomy 13)
      • 5.2.3.4. Turner Syndrome (Monosomy X)
      • 5.2.3.5. Others
    • 5.2.4. By End-user
      • 5.2.4.1. Hospitals
      • 5.2.4.2. Diagnostic Laboratories
      • 5.2.4.3. Clinics
    • 5.2.5. By Country Share
      • 5.2.5.1. United States
      • 5.2.5.2. Canada
      • 5.2.5.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Product
          • 5.3.1.2.1.1. Instruments
          • 5.3.1.2.1.2. Consumables
          • 5.3.1.2.1.2.1. Kits
          • 5.3.1.2.1.2.2. Reagents
        • 5.3.1.2.2. By Method
          • 5.3.1.2.2.1. Next Generation Sequencing (NGS)
          • 5.3.1.2.2.2. Polymerase Chain Reaction (PCR)
          • 5.3.1.2.2.3. Cell-free DNA (cfDNA)
          • 5.3.1.2.2.4. Others
        • 5.3.1.2.3. By Application
          • 5.3.1.2.3.1. Down Syndrome (Trisomy 21)
          • 5.3.1.2.3.2. Edwards Syndrome (Trisomy 18)
          • 5.3.1.2.3.3. Patau Syndrome (Trisomy 13)
          • 5.3.1.2.3.4. Turner Syndrome (Monosomy X)
          • 5.3.1.2.3.5. Others
        • 5.3.1.2.4. By End-user
          • 5.3.1.2.4.1. Hospitals
          • 5.3.1.2.4.2. Diagnostic Laboratories
          • 5.3.1.2.4.3. Clinics
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Turkey
  • 6.9. Poland

7. Asia-Pacific Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Illumina, Inc.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. Eurofins LifeCodexx GmbH
    • 20.3.3. Myriad Genetics, Inc.
    • 20.3.4. Natera, Inc.
    • 20.3.5. CENTOGENE N.V.
    • 20.3.6. PerkinElmer Inc.
    • 20.3.7. F. Hoffmann-La Roche Ltd
    • 20.3.8. MedGenome Labs Limited
    • 20.3.9. Laboratory Corporation of America Holdings
    • 20.3.10. BGI Genomics Co., Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 3. Global Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 4. Global Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 5. Global Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 6. Global Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 8. North America Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 9. North America Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 10. North America Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 11. North America Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 12. North America Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 14. United States Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 15. United States Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 16. United States Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 17. United States Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 18. Canada Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Canada Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 20. Canada Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 21. Canada Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 22. Canada Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 23. Mexico Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Mexico Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 25. Mexico Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 26. Mexico Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 27. Mexico Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 28. Europe Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Europe Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 30. Europe Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 31. Europe Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 32. Europe Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 33. Europe Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Germany Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 36. Germany Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 37. Germany Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 38. Germany Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 39. France Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 40. France Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 41. France Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 42. France Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 43. France Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 44. Italy Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Italy Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 46. Italy Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 47. Italy Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 48. Italy Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 49. United Kingdom Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. United Kingdom Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 51. United Kingdom Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 52. United Kingdom Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 53. United Kingdom Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 54. Russia Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 55. Russia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 56. Russia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 57. Russia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 58. Russia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 59. Netherlands Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Netherlands Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 61. Netherlands Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 62. Netherlands Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 63. Netherlands Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 64. Spain Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Spain Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 66. Spain Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 67. Spain Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 68. Spain Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 69. Turkey Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Turkey Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 71. Turkey Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 72. Turkey Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 73. Turkey Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 74. Poland Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Poland Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 76. Poland Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 77. Poland Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 78. Poland Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 79. South America Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 80. South America Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 81. South America Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 82. South America Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 83. South America Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 84. South America Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Country, 2018-2032F
  • Figure 85. Brazil Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. Brazil Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 87. Brazil Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 88. Brazil Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 89. Brazil Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 90. Argentina Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Argentina Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 92. Argentina Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 93. Argentina Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 94. Argentina Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 95. Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 96. Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 97. Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 98. Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 99. Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 100. Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Country, 2018-2032F
  • Figure 101. India Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. India Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 103. India Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 104. India Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 105. India Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 106. China Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. China Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 108. China Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 109. China Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 110. China Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 111. Japan Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 112. Japan Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 113. Japan Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 114. Japan Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 115. Japan Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 116. Australia Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 117. Australia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 118. Australia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 119. Australia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 120. Australia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 121. Vietnam Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 122. Vietnam Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 123. Vietnam Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 124. Vietnam Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 125. Vietnam Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 126. South Korea Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 127. South Korea Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 128. South Korea Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 129. South Korea Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 130. South Korea Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 131. Indonesia Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. Indonesia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 133. Indonesia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 134. Indonesia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 135. Indonesia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 136. Philippines Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 137. Philippines Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 138. Philippines Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 139. Philippines Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 140. Philippines Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 141. Middle East & Africa Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 142. Middle East & Africa Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 143. Middle East & Africa Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 144. Middle East & Africa Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 145. Middle East & Africa Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 146. Middle East & Africa Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. Saudi Arabia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 149. Saudi Arabia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 150. Saudi Arabia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 151. Saudi Arabia Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 152. UAE Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 153. UAE Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 154. UAE Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 155. UAE Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 156. UAE Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 157. South Africa Non-Invasive Prenatal Testing (NIPT) Market, By Value, In USD Billion, 2018-2032F
  • Figure 158. South Africa Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Product, 2018-2032F
  • Figure 159. South Africa Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Method, 2018-2032F
  • Figure 160. South Africa Non-Invasive Prenatal Testing (NIPT) Market Share (%), By Application, 2018-2032F
  • Figure 161. South Africa Non-Invasive Prenatal Testing (NIPT) Market Share (%), By End-user, 2018-2032F
  • Figure 162. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 163. By Method Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 164. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 165. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024